{
  "abstract": "Tiffany E Jiang, Reshma Ramachandran, and Joshua J Skydel argue that US requirements for interchangeability are not supported by evidence and hamper use of biosimilars",
  "authors": [
    {
      "affiliations": [
        "Yale School of Medicine, New Haven, CT, USA",
        "Yale Collaboration for Regulatory Rigor, Integrity and Transparency, Yale School of Medicine, New Haven, CT, USA"
      ],
      "name": "Tiffany E Jiang"
    },
    {
      "affiliations": [
        "Yale Collaboration for Regulatory Rigor, Integrity and Transparency, Yale School of Medicine, New Haven, CT, USA",
        "Section of General Internal Medicine, Yale School of Medicine, New Haven, CT, USA"
      ],
      "name": "Reshma Ramachandran"
    },
    {
      "affiliations": [
        "Yale Collaboration for Regulatory Rigor, Integrity and Transparency, Yale School of Medicine, New Haven, CT, USA",
        "Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, USA"
      ],
      "name": "Joshua J Skydel"
    }
  ],
  "title": "Regulatory change could improve biosimilar access in the US",
  "uid": "f4803420-2a50-5a41-a372-d5fbbced5f45"
}